We Broke the Script: Why Medicine Is Reimbursing You for Getting Sicker
Let me say the uncomfortable thing first. Most of medicine is not failing because doctors don’t care.
It’s failing because we built a system that pays for disease and then trained an entire profession to operate inside it — and then spent fifty years wondering why we keep getting more disease.
This is not a post about physician villains. It’s a post about structural capture — and what it would actually take to break out of it.
What We Built and Why It Made Sense (Once)
The insurance and reimbursement architecture in the United States — and to varying degrees across the OECD — was designed in an era when the dominant medical threat was acute illness. Infection. Trauma. Surgical emergencies. In that context, fee-for-service made sense. You intervene, you get paid for the intervention, the patient recovers. Done.
The problem is that we kept that model running straight into an epidemic of chronic metabolic disease — conditions that take decades to develop, require sustained behavioral change to manage, and produce almost no billable events until the catastrophic endpoints: the MI, the stroke, the dialysis chair, the amputation.
At that point, we bill extremely well.
The perversity is not accidental. It is structural. And structure, far more than intent, shapes behavior.
The Hamster Wheel Is the Business Model
A primary care physician in the United States sees an average of 20 to 25 patients per day. At that volume, the average visit time is 13 to 18 minutes — a number that has not meaningfully changed in three decades, even as the complexity of the average patient has increased substantially. Somewhere between 20 and 30 percent of that time is consumed by documentation requirements that exist not for clinical purposes but for billing validation.
What does a physician actually have time to do in a 13-minute slot with a patient who has type 2 diabetes, hypertension, prediabetes, and probable insulin resistance underlying all of it?
They can address the chief complaint. They can renew prescriptions. They can order labs. They cannot have a 45-minute conversation about the metabolic consequences of the patient’s diet, sleep architecture, and sedentary work pattern. That conversation exists nowhere in the reimbursement structure. It is invisible to the billing system.
So it doesn’t happen.
Not because the physician doesn’t know it matters. Because the system they’re operating inside has no mechanism to reward it — and a very efficient mechanism to penalize them for the time it would take.
This is not a failure of character. It is a failure of incentive architecture.
What We Are Actually Paying For
Consider what gets reimbursed at premium rates in the current system:
A 10-minute procedure generates more revenue than a 90-minute motivational interviewing session
Prescribing a statin takes 45 seconds and bills efficiently; helping a patient restructure their eating pattern over 12 weeks does not exist as a reimbursable interaction
A hospitalization for acute decompensated heart failure generates tens of thousands of dollars; the conversation that might have prevented it — about sodium, exercise tolerance, and medication adherence — generates nothing
Specialty referrals are billable; follow-up integration of specialist findings into longitudinal care is not
We have built a system that is financially indifferent to prevention and financially enthusiastic about rescue. Then we act surprised that we spend more per capita on healthcare than any nation on earth while producing some of the worst chronic disease outcomes in the developed world.
This is not a bug in the design. It is the design.
The Evidence We Are Ignoring
The clinical literature on lifestyle intervention as disease-modifying treatment is no longer experimental. It is settled.
The Diabetes Prevention Program showed that intensive lifestyle modification reduced the incidence of type 2 diabetes by 58 percent — outperforming metformin. The Mediterranean diet trials have demonstrated cardiovascular event reduction comparable to statin therapy in high-risk populations. Resistance training data across multiple prospective cohort studies consistently show inverse relationships with all-cause mortality, cardiovascular mortality, and metabolic disease incidence. Sleep science over the last fifteen years has established that insufficient sleep is not a personal failing but a metabolic risk factor — dysregulating appetite hormones, impairing glucose disposal, and accelerating visceral adiposity.
None of this is fringe. All of it is published in journals you know. Most of it has not meaningfully changed clinical practice, because clinical practice is driven not by evidence alone but by evidence that can be converted into a reimbursable action.
A prescription is a reimbursable action. A referral is a reimbursable action. A detailed conversation about resistance training periodization, protein targets, and chronobiology is, in most systems, not.
The PMOS Problem Is a Case Study in This Failure
The May 2026 Lancet reclassification of PCOS to Polyendocrine Metabolic Ovarian Syndrome — PMOS — is not just a nomenclature revision. It is an indictment of how we approached this condition for four decades.
PCOS affected somewhere between 10 and 13 percent of women of reproductive age globally. For most of that time, it was treated as a gynecological condition — managed with oral contraceptives to regulate cycles, metformin to address insulin resistance, and fertility treatments when needed. Those are all legitimate interventions. They are also all downstream of the actual disease process.
The fundamental pathology is a primary endocrine-metabolic disruption — driven by insulin resistance, androgen dysregulation, and chronic low-grade inflammation — that produces reproductive consequences as a secondary manifestation. When we treated the reproductive consequences, we were treating the smoke. The fire was metabolic.
Why did it take forty years to reframe this? Partly because the science required time. But partly because the reimbursement system incentivized gynecological intervention and had no efficient pathway to reimburse what we now understand the condition actually requires: metabolic risk stratification, continuous glucose monitoring, dietary intervention, structured exercise prescription, and longitudinal endocrine management.
When you pay for procedures, you get a procedure-oriented specialty. PMOS is what happens when you apply that incentive structure to a metabolic disease and call it gynecology.
From Medicine 3.0 to Physiology-First: Advancing the Conversation
Before going further, I want to be direct about intellectual lineage.
Peter Attia’s Medicine 3.0 framework — most fully articulated in Outlive — deserves genuine credit for shifting the cultural conversation inside medicine. His argument, that modern healthcare is reactive by design and that the window for intervention is decades earlier than we typically act, is correct and important. He gave a generation of clinicians and educated patients a language for what many of us had been trying to do clinically without a coherent framework to stand behind. That matters.
But Medicine 3.0 answers the question of when to intervene — much earlier — without fully answering the question of where to intervene at the mechanistic level. It advances the timeline without fully reorienting the target.
The frame I want to propose — and the one I think the PMOS reclassification makes scientifically necessary — is Physiology-First Medicine. The distinction is not semantic.
Pathology-first medicine, which is what we currently practice, waits for a disease state to declare itself and then manages it. It reimburses rescue. Physiology-first medicine asks a different prior question: is the underlying biological system — metabolic function, endocrine signaling, inflammatory tone, musculoskeletal capacity, sleep architecture — operating within a range that makes chronic disease unlikely? If not, the intervention happens there, before a disease category exists to bill against.
The reimbursement sentence that captures the entire problem: pathology-first medicine pays for the flood; physiology-first medicine pays for the watershed.
This is not just an earlier version of the same approach. It is a different causal model. And the PMOS reclassification is the clearest recent example of what happens when science catches up to a physiology-first frame that clinical practice — and reimbursement architecture — never adopted.
Outcome metrics that matter:
Physiology-first medicine measures physiological function longitudinally — VO2 max trajectory, muscle mass indexed to body weight, continuous glycemic variability, visceral fat quantification, inflammatory burden, sleep architecture quality. These are the metrics that predict long-term health outcomes with far more precision than the episodic labs we currently capture. They are not waiting for pathology. They are mapping the terrain before the flood.
Most of these are not standard of care. Several are not consistently reimbursed.
The muscle imperative:
Skeletal muscle is the largest metabolic organ in the body. Its mass, its function, and its rate of preservation or atrophy are among the most powerful predictors of metabolic health, insulin sensitivity, bone density, and survivorship into older age. The evidence for resistance training as a therapeutic modality — not exercise as general wellness advice, but structured, progressive resistance training as disease-modifying intervention — is now substantial enough that its absence from standard clinical practice represents a genuine gap.
We do not teach physicians to prescribe resistance training. We do not reimburse exercise physiologists embedded in primary care teams. We do not measure muscle mass as a metabolic health indicator in routine clinical encounters.
We do reimburse GLP-1 agonists extremely well. Those are legitimate tools. They are also not a substitute for muscle, and they are being deployed at scale in a system that has no mechanism to ensure the muscle preservation that determines their long-term utility.
Nutrition as medicine:
The evidence base for dietary intervention in metabolic disease — particularly carbohydrate-restricted and Mediterranean approaches in insulin-resistant populations — is now large enough that dismissing it as “lifestyle advice” is no longer scientifically defensible. It is a clinical intervention. It requires time, expertise, and sustained follow-up to implement effectively. It is not reimbursed as such in most systems.
How We Change the Reimbursement Structure
This is where most advocacy pieces become platitudinous, so let’s try to be specific.
